Youcare Pharmaceutical (SH:688658) Shang Hai Zheng Quan Bao·2026-01-21 18:41Core Viewpoint - The announcement details the expected daily related transactions for 2026 by Youcare Pharmaceutical Group Co., Ltd, which are based on normal business operations and market prices, ensuring no impact on the company's independence or shareholder interests [2][3][30]. Group 1: Daily Related Transactions Overview - The total expected amount for daily related transactions in 2026 is estimated at 241.56 million RMB [3]. - The board of directors, excluding related directors, unanimously approved the proposal for these transactions [3][4]. - Independent directors confirmed that the transactions are necessary for the company's operations and do not harm the interests of shareholders, especially minority shareholders [3][30]. Group 2: Related Parties and Their Financials - Related parties include Anhui Hengshun Information Technology Co., Ltd, with total assets of 1.19 billion RMB and a net loss of 22.79 million RMB for 2025 [11][12]. - Beijing Yuantong Kangbai Pharmaceutical Co., Ltd reported total assets of 491.69 million RMB and a net loss of 16.34 million RMB for 2025 [13][14]. - Other related parties include Beijing Kaicheng Yichuang Technology Co., Ltd, with total assets of 64.70 million RMB and a net loss of 6.13 million RMB for 2025 [16][17]. Group 3: Transaction Details and Pricing Principles - The main content of the expected transactions includes sales of products, procurement of goods and services, and leasing of properties between the company and related parties [27]. - Pricing for these transactions will follow government pricing, market prices, and negotiated agreement prices to ensure fairness [28]. - The company will sign specific contracts with related parties after board and shareholder approval [29]. Group 4: Necessity and Impact of Related Transactions - The related transactions are deemed necessary for maintaining supply chain stability and improving internal management efficiency [30]. - The pricing of these transactions is considered fair and reasonable, with no significant differences from external non-related third-party prices [31]. - The volume of related transactions is low compared to the company's main business income, ensuring no dependency on related parties [32].